Given the emerging role of PD-L1 inhibitors including durvalumab and PD-1 inhibitors such as pembrolizumab in the treatment of non-small cell lung cancer, clinicians will often confront the dilemma of their use in patients with IPF and concomitant lung cancer [43–49]. This evidence concerns the gene PDCD1 and lung cancer.